ERBB2 and neoplasm: The above preclinical data suggesting greater anti-tumor activity with HER2 ADCs than kinase inhibitors in urothelial cancer is supported by our real-world clinical experience with T-DXd in patients with metastatic urothelial cancer (Fig. 6A).